| Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
|
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
|
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
| Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
